Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Murakami, Haruyasu, Nokihara, Hiroshi, Hayashi, Hidetoshi, Seto, Takashi, Park, Keunchil, Azuma, Koichi, Tsai, Chun‐Ming, Yang, James Chih‐Hsin, Nishio, Makoto, Kim, Sang‐We, Kiura, Katsuyuki, Inoue, Akira, Takeda, Koji, Kang, Jin‐Hyoung, Nakagawa, Tomoki, Takeda, Kentaro, Akazawa, Rio, Kaneko, Yuichiro, Shimazaki, Masashi, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125469/
https://ncbi.nlm.nih.gov/pubmed/29972716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13724
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados